Biotechnology
News Category

NanoViricides Advances NV-387 into Phase 2 Trials for Ebola and Mpox, Eyes Measles with FDA Designations
NanoViricides has initiated two Phase 2 clinical trials for its broad-spectrum antiviral NV-387 in Ebola and mpox, while leveraging FDA designations t...

Nutriband's USPTO Allowance for Fentanyl Patch Brand Names Signals Progress Toward Market Launch
Nutriband Inc. received a USPTO Notice of Allowance for brand names tied to its abuse-deterrent fentanyl patch, advancing regulatory and commercial pr...

Sino Biological Launches AI-Trusted and AI-Qualified Protein Collections to Validate AI-Designed Molecules
Sino Biological introduces two curated target protein collections, AI-Trusted and AI-Qualified, providing experimentally characterized proteins essent...

Cardio Diagnostics Schedules Dec. 10 Investor Call to Detail FDA Breakthrough Device Plans and NOCAD Detection Strategy
Cardio Diagnostics Holdings will host a Dec. 10 investor call to outline its FDA Breakthrough Device designation strategy, non-obstructive coronary ar...

VolitionRx Expands Fujifilm Vet Systems Agreement to Develop Feline Cancer Test in Japan
VolitionRx's expanded agreement with Fujifilm Vet Systems to develop a feline cancer test in Japan opens a potential revenue stream in a market with n...

iPSC Neural Models Offer Disease-Relevant Alternatives for Early Drug Discovery
Creative Biolabs is promoting complementary iPSC differentiation, neural model, and microfluidic culture solutions to help researchers select laborato...

Quantum BioPharma's $12.22M Cash and Digital Assets Fuel Lucid-MS Phase 2 Trial
Quantum BioPharma reported $12.22 million in cash and digital assets and advancing its Lucid-MS Phase 2 trial, signaling improved financial health and...

MindBio's AI Voice Tech Hits 83% Intoxication Detection Accuracy, Eyes Commercial Pilot
MindBio Therapeutics reports up to 83% accuracy in AI-driven voice intoxication detection, surpassing some cheek swab tests, and announces a $350,000 ...

CNS Pharmaceuticals Reports Q3 2026 Financials and Advances Pipeline Expansion Strategy
CNS Pharmaceuticals reported a narrowed Q3 2026 net loss and a strengthened cash position, while advancing discussions to acquire or license new thera...

Helus Pharma's Q2 Results Highlight Phase 3 Progress and Pipeline Expansion
Helus Pharma reported a wider net loss but completed enrollment in its pivotal Phase 3 trial for HLP003, signaling progress toward addressing major de...

Personalized Vaccines Extend Survival in Brain Cancer, Signaling New Era in Treatment
Personalized vaccines are showing promise in extending survival for glioblastoma patients, with UCLA's trial results offering hope and prompting broad...

Quantum Computing's Slow Path to the Pharmacy
Quantum computing could reshape drug discovery by solving complex molecular problems, but technical hurdles mean practical adoption remains years away...

Helus Pharma's Phase 3 Success for HLP003 in MDD Signals Potential New Treatment Option
Helus Pharma's positive Phase 3 results for HLP003 in major depressive disorder demonstrate statistically significant and rapid improvements, potentia...

Quantum BioPharma's $12.22 Million in Cash and Digital Assets Fuels Lucid-MS Phase 2 Trial
Quantum BioPharma's Q3 2026 results show $12.22 million in cash and digital assets, a 91% equity increase, and a key Phase 2 trial agreement for Lucid...

Oragenics Secures NYSE American Listing Extension Through 2028
Oragenics receives a compliance extension from NYSE American through February 2028, allowing the clinical-stage biopharmaceutical company to maintain ...

Sino Biological Launches 4RISE™ to Speed AI-Designed Binder Validation
Sino Biological's 4RISE™ high-throughput wet-lab services aim to bridge the gap between AI-driven protein design and experimental validation, offering...

Redwood AI Adds Chemical Risk Evaluator to Reactosphere Platform
Redwood AI's new CARE feature integrates safety screening into its Reactosphere synthesis platform, enabling chemists to identify and mitigate risks e...

Creative Biolabs Pairs AI Antibody Design with Developability Checks to Guide Go/No-Go Decisions
Creative Biolabs is integrating AI-driven antibody design and optimization with early developability assessment to help biopharma teams prioritize can...

Novogenia to Supply DNA Analytics and Personalized Supplements for GLP-1 Clinical Study in Abu Dhabi
Novogenia AG will conduct DNA analyses and manufacture personalized dietary supplements for a planned 500-participant clinical study in Abu Dhabi, aim...

Immunotherapy Eliminates Brain Tumors in Preclinical Study, Human Trials Planned
A new immunotherapy wiped out all tumor cells in mice with brain tumors, prompting researchers to accelerate human trials, which could begin as early ...

Resilient Performance Group Flags Unpriced 'Landing Gap' in Cross-Border Biotech Deals
Resilient Performance Group has identified a critical commercial exposure—the Landing Gap—that is going unpriced as pharmaceutical companies acquire o...

BioVersys to Unveil New Alpibectir Data at The Union World Conference on Lung Health
BioVersys and GSK will present Phase 2 data on alpibectir-ethionamide for tuberculosis at The Union World Conference, potentially advancing a much-nee...

Quantum BioPharma Insider Voting Control Rises to 68.22% After Private Placement
Quantum BioPharma closed a private placement of Class A multiple voting shares to insiders, increasing their aggregate voting power to 68.22% and cons...

Onco-Innovations Terminates Sorbie Funding Arrangement, Cancels 5.38 Million Shares
Onco-Innovations agreed to terminate its performance-based funding arrangement with Sorbie, canceling 5.38 million shares and eliminating 2.25 million...

Quantum BioPharma Private Placement Lifts Insider Voting Power to 68.22%
Quantum BioPharma's issuance of 26 Class A multiple voting shares to entities tied to its CEO and a director increased insider voting control from 57....

Creative Biolabs Highlights Complementary Single-Cell RNA Methods to Address Research Blind Spots
Creative Biolabs is promoting three distinct RNA profiling and visualization approaches to help researchers overcome limitations in studying cellular ...

Lantern Pharma Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial
Lantern Pharma's publication of Phase 1a data for LP-184 in recurrent glioblastoma establishes a dosing rationale for a planned Phase 1b/2a trial comb...

MIT's Engineered Donor Immune Cells Eliminate Lymphoma in Mice Within Three Weeks, Signaling New Immunotherapy Path
MIT researchers have engineered donor immune cells that wiped out lymphoma in mice within three weeks without being rejected, offering a potentially f...

NanoViricides Advances NV-387 Toward Phase II Trials for Measles
NanoViricides is advancing its broad-spectrum antiviral NV-387 toward Phase II clinical trials for measles, addressing a rising unmet medical need wit...

Sino Biological Launches 4RISE™ to Accelerate AI-Designed Molecule Validation
Sino Biological's new 4RISE™ platform integrates rapid expression and multi-dimensional validation to bridge the gap between AI-generated protein desi...

Tonix Pharmaceuticals Q3 2026 Revenue Jumps to $17.2 Million on TONMYA Strength
Tonix Pharmaceuticals reported third-quarter 2026 net product revenue of $17.2 million, driven by 37% sequential growth in TONMYA sales, and extended ...

Lifordi's LFD-200 Shows Early Promise in Delivering Glucocorticoids Without Systemic Toxicity
Lifordi Immunotherapeutics' Phase 1 data for LFD-200, a subcutaneous antibody-drug conjugate, demonstrates tolerability and anti-inflammatory effects ...

GeoVax Announces 1-for-24 Reverse Stock Split to Regain Nasdaq Compliance
GeoVax Labs will implement a 1-for-24 reverse stock split on November 11, 2026, to raise its share price above the $1.00 minimum bid required for cont...

Quantum BioPharma Clarifies Share Consolidation Terms Ahead of Shareholder Meeting
Quantum BioPharma files a supplement to clarify share consolidation terms, including fractional share rounding and a 70% voting power cap, ahead of it...

Boston Symposium to Tackle Unanswered Questions in Human Egg Activation
The 2026 Activated Egg Symposium will convene leading scientists in Boston to address fundamental questions about human egg activation, with implicati...

German Court Upholds Cancellation of CeramTec's Pink Trademark, Bolstering CoorsTek's Competitive Position
A German federal patent court ruling upholding the cancellation of CeramTec's pink trademark for ceramic hip components strengthens CoorsTek Biocerami...

Annovis Bio's $21 Million Offering to Fund Buntanetap Phase 3 Trials for Alzheimer's and Parkinson's
Annovis Bio's $21 million public offering will fund continued clinical development of buntanetap, a potential disease-modifying therapy for Alzheimer'...

Kairos Pharma Wins 2026 Biotech Breakthrough Award for Cancer Immunology
Kairos Pharma's ENV-105 received the 2026 Biotech Breakthrough Award for Cancer Immunology, highlighting its potential to overcome treatment resistanc...

High-Risk Antibiotic Prescribed to 20% of Dental Infection Patients, Raising Concerns
A new study reveals that one in five patients with dental infections receives a high-risk antibiotic, highlighting urgent gaps in prescribing practice...

Scinai Immunotherapeutics Posts 167% Revenue Jump as CDMO Orders Swell Past $8.3 Million
Scinai Immunotherapeutics reported 167% revenue growth to $2.8 million and more than $8.3 million in committed customer orders, signaling that its con...

Annovis Bio's Proposed Public Offering to Fund Buntanetap Trials for Alzheimer's and Parkinson's
Annovis Bio's proposed public offering aims to raise capital to advance its lead drug candidate buntanetap through clinical development for Alzheimer'...

Viromed Gains Early Approval for ViroCAP® med in Turkey, Accelerating Cold Plasma Market Entry
Viromed Medical AG has received approval for its ViroCAP® med cold plasma device in Turkey ahead of schedule, securing binding orders and advancing it...

Heidelberg Pharma to Unveil Pivotal Phase I/IIa Data for ATAC Candidates at ASH 2026
Heidelberg Pharma will present new clinical data for its Amanitin-based ADC candidates pamlectabart tismanitin (HDP-101) and HDP-102 at the 68th ASH A...

Tonix Pharmaceuticals to Present at Guggenheim Healthcare Innovation Conference, Spotlighting Commercial-Stage CNS and Immunology Strategy
Tonix Pharmaceuticals' upcoming presentation at the Guggenheim Healthcare Innovation Conference highlights its commercial-stage portfolio, including t...

Quantum BioPharma's Dual Strategy Targets Neurological Disorders and Consumer Wellness
Quantum BioPharma is advancing a diversified strategy that pairs its lead drug candidate Lucid-MS for demyelination with consumer wellness products an...

October Wellness Index Report Reframes Aging as an Engineering Problem
Wellness Eternal's October 2026 Wellness Index Report spotlights three experts who treat healthspan as something to be engineered, signaling a shift f...

